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ABSTRACT
The present studies were designed for investigation of the requirements for cytotoxic function in donor T-cells
transplanted to support engraftment after infusion of allogeneic bone marrow. The experiments examined the
capacity of donor CD8+ T-cells lacking Fas ligand and/or perforin function to facilitate donor B6 congenic (B6-
Ly5.1) BM engraftment across major histocompatibility complex class I/II barriers after transplantation. T-cell–
depleted BM cells from B6-Ly5.1 donors were transplanted into sublethally irradiated (5.5 Gy) BALB/c recipients
together with different lymphocyte populations from wild-type B6 (B6-wt) donors or donors lacking functional
cytotoxic pathways. Early presence of lineage-committed donor progenitor cells was assessed by the presence of day
5 splenic colony-forming units–granulocyte-macrophage (CFU-GM). Recipients of BMT without donor T-cells did
not demonstrate significant CFU-GM activity 5 days post-BMT. Lineage-committed progenitor cells in recipient
spleens could be supported by addition to the BM of wild-type (B6-wt) and cytotoxically single- (perforin, B6-pko
or FasL, B6-gld) or double-deficient (B6-cdd) CD8+ T-cells. However, B220+-enriched B-cells could not support
the presence of day 5 donor CFU-GM. For further assessment of the capacity of cytotoxically impaired T-cells to
participate in the engraftment process, the ability of these and normal CD8 cells to support the homing of donor
cells to the BM was examined after infusion of carboxyfluorescein diacetete succinimidyl ester–labeled progenitors.
In a syngeneic model lacking resistance, cytotoxically impaired donor T-cells supported increased numbers of pro-
genitor cells in the marrow equivalent to the support provided by wild-type donor T-cells. Examination of periph-
eral chimerism indicated that during the first month after B6→BALB/c BMT, donor chimerism was detected in
BMT recipients receiving unfractionated T-cells or CD8+ T-cells from B6-wt donors, and chimerism was main-
tained at least 80 days after BMT. In contrast, B6-cdd unfractionated or CD8+ T-cells failed to maintain long-term
B6 donor chimerism in the host. Experiments with highly enriched populations of positively selected CD8+ T-cells
from B6-pko, B6-gld, or B6-cdd donors demonstrated that although each of these T-cell populations could pro-
mote the initial presence of donor CFU-GM early post-BMT, B6-pko and B6-cdd CD8+ T-cell populations were
not able to support long-term peripheral chimerism. These results demonstrate that donor T-cells lacking major
cytotoxic effector pathways have functions that support initial donor progenitor cell presence in the host hemato-
poietic compartment after BMT. They also demonstrate that support of long-term donor BM engraftment
requires CD8+ T-cells with intact cytotoxic, that is, perforin, function. Finally, syngeneic B6→B6 BMT suggests
activation of CD8+ T-cells posttransplantation apparently is required to support enhanced progenitor cell activity.
This study provides new findings concerning the role of cytotoxic function in the process of facilitating allogeneic
donor BM engraftment.
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INTRODUCTION
Both experimental and clinical studies have demon-
strated that depletion of T-cells from allogeneic donor
bone marrow (BM) frequently results in graft failure. The
ﬁndings support a role for donor T-cell–mediated functions
in successful BM engraftment [1]. Two mechanisms that are
not mutually exclusive have been proposed by which T-cells
may support donor marrow engraftment: (1) donor T-cells
can provide necessary lymphokines for donor stem cell dif-
ferentiation and proliferation [2-4] and (2) donor T-cells
can prevent grafted stem cells from being rejected by
exerting effector function and eliminating residual host
resistance [5]. Engraftment following progenitor cell trans-
plantation appears to take place in 2 phases. Rapid reconsti-
tution early post-BMT followed by a slower but more stable
long-term reconstitution has been observed [6]. Some
investigators have proposed that the early reconstitution
was established by lineage-committed progenitor cells
whereas the long-term engraftment was due to the multi-
potential hematopoietic stem cells (HSC) contained in the
transplant. Other investigators, however, have reported that
both early and long-term reconstitution can result from the
engraftment of donor HSC, not colony-forming committed
progenitor cells [7,8].
The requirements for achieving early and long-term
reconstitution of donor marrow cells remain to be clearly
defined. In this study, a colony-forming assay was used for
analysis of the initial seeding into H-2d recipients of allo-
geneic H-2b lineage-committed progenitor cells on days 5
and 12 post-BMT. Long-term reconstitution was evalu-
ated by phenotypic analysis of the donor/host origin of
circulating peripheral-blood mononuclear cells (PBMC).
Addition of donor T-cells with defined cytotoxic deficien-
cies to T-cell–depleted (TCD) marrow inoculum enabled
evaluation of the role of both Fas ligand and perforin-
mediated lytic pathways in promoting the initial seeding of
allogeneic donor marrow and long-term engraftment. The
results demonstrated that initial seeding and early presence
of lineage-committed progenitor cells could be accom-
plished without the presence of both perforin and Fas ligand
function in donor lymphocytes. However, some T-cell func-
tion was clearly required for lineage-committed progenitor
cell presence posttransplantation because addition of a
donor B220+ B-cell–enriched population failed to promote
the appearance of donor colony-forming units (CFU) in
recipient spleens. To remove the requirement to overcome
resistance post-BMT, we performed experiments with a
syngeneic model to assess whether cytotoxically impaired
T-cells could support the early presence of donor pro-
genitor cells in the host marrow compartment. Such perforin/
FasL defective T-cells functioned equivalently to normal
T-cells in ability to augment the numbers of donor cells
found in the marrow early posttransplantation. In contrast,
long-term allogeneic hematopoietic reconstitution required
cytotoxic function, specifically perforin function by donor
T-cells added to promote marrow engraftment. These
results support the notion that facilitating cells employ mul-
tiple functions to support the engraftment process. The
ﬁndings may also suggest that differing functions of “facili-
tating” T-cells may be important during different phases of
the engraftment process.
MATERIALS AND METHODS
Mice
Six- to 8-week-old female BALB/c, B6.SJL-CD45aPepb/
BoyJ (B6-Ly5.1), and C57BL/6 mice were purchased from
Jackson Laboratories (Bar Harbor, ME). B6Smn.C3H-
Tnfsf6gld, FasL mutant (B6-gld), and C57BL/6-Pfptm1Sdz, per-
forin knock-out mice (B6-pko) were originally provided by
Dr. Eckhard Podack. B6-GFP [Tg14(act-EGFP)OsbY01]
mice were originally obtained from Dr. Masaru Okabe
(Osaka University, Osaka, Japan). C57BL/6 cytotoxically
double-deﬁcient (perforin and Fas) mice (B6-cdd) were gen-
erated from the breeding of B6-pfp+/– Fasl gld/gld pairings as
described previously [9]. To select for B6-pfp–/–Fasl gld/gld
(B6-cdd), we used a polymerase chain reaction to screen the
offspring for homozygous perforin deficiency [10]. Six- to
8-week-old B6-cdd and B6-pfp–/– (B6-pko) mice maintained
in pathogen-free conditions in the department of microbi-
ology and immunology at the University of Miami School
of Medicine were used as donors for all experiments.
BM Transplantation
A major histocompatibility complex (MHC) class I/II
mismatched graft-versus-host disease model was used in
which BALB/c mice (H-2d) were recipients. One day before
transplantation, BALB/c (or syngeneic H-2b) recipients were
conditioned with varying doses of total body irradiation (TBI)
(cobalt 60 source; dose rate, 44.5 cGy/min). BM cells
obtained by flushing of donor B6-Ly5.1 femurs and tibias
were resuspended at a concentration of 2.5 × 107/mL in
RPMI-1640 medium and incubated with anti-Thy1.2 murine
antibodies (mAb) (HO13.2) at 4°C for 30 minutes. The cells
were then washed and incubated at 37°C for 45 minutes in
the presence of complement (Rabbit Low Tox-M, Cedarlane
Laboratories, Hornby, Ontario, Canada). After being washed
with RPMI-1640 medium, TCD BM cells were collected,
and the viable cells were counted with trypan blue staining.
TCD BM cells (5 × 106) from MHC class I/II mismatched
B6-Ly5.1 donors were injected intravenously into BALB/c
recipients alone (control) or with selected numbers of B6-wt,
B6-pko, B6-gld, or B6-cdd T-cells or B-cells. A minimum of 2
BMT recipients per time point were used in each study.
Lymphocyte Preparation
T-cells were prepared from donor spleen and lymph
nodes. B-cells were removed by 2 rounds of panning on anti-
sIg coated plates. This procedure was followed by incubation
with anti-B220 mAb (14.8) plus goat anti-rat mAb (18.5) and
complement (Cedarlane). More than 85% purity of T-cells
was obtained. Highly enriched CD8+ T-cells were obtained
by positive selection with the Miltenyi magnetic cell sorting
system (MACS) (Miltenyi, Auburn, CA). Donor spleen and
lymph node cells were suspended in phosphate-buffered
saline solution (PBS) containing 0.5% bovine serum albumin
(BSA) at 1 × 108/mL and labeled with anti-CD8 conjugated
magnetic beads by incubation for 15 minutes at 4°C. The
cells were then washed and resuspended in PBS/0.5% BSA
and loaded onto a MACS separation column in a magnetic
field. The unlabeled cells were removed by 3 washes with
PBS/0.5% BSA, and CD8+ cells were eluted from the col-
umn with the same buffer outside the magnetic field. In
some experiments, B-cell populations were prepared by posi-
Z. Jiang et al.
590
tive selection with the Miltenyi MACS system. Donor spleen
cells were incubated with ﬂuorescein isothiocyanate (FITC)
anti-B220 for 15 minutes and then with anti-FITC conju-
gated magnetic beads for 15 minutes. The B220+ B-cells
were then positively selected by binding to the MACS col-
umn followed by elution. Enriched cell populations were
stained with Cy-Chrome anti-CD8, phycoerythrin (PE)
anti-CD4, and FITC anti-B220 (Pharmingen, San Diego,
CA) mAbs and examined for purity by ﬂow cytometric analy-
sis with a FACScan system (Becton Dickinson, Franklin
Lakes, NJ). The purity of T-cell and B-cell populations
obtained after the enrichment protocol was always >90%.
Spleen Colony-Forming Assay
The CFU-GM and CFU–interleukin 3 (IL-3) assays were
modiﬁed from a previously described method [11]. Recipients
were killed on day 5 or day 12 post-BMT, and the nucleated
spleen cells were counted. The spleen cells (2.5 × 105) were
cultured in 1 mL mixture containing α modiﬁcation of Eagle’s
medium with nucleotides (α-MEM), 0.86% methycellu-
lose (Methocult, StemCell Technologies, Vancouver, BC),
30% fetal calf serum, 250µM 2-mercaptoethanol, 2mM
L-glutamine, 100 U/mL penicillin, 100 µg/mL streptomycin
and 50 U/mL recombinant murine granulocyte-macrophage
colony-stimulating factor, or recombinant murine IL-3 (R&D
Systems, Minneapolis, MN). Cultures were established in trip-
licate and maintained at 37°C in humidiﬁed air with 5% CO2
for 5 days. Cell aggregates containing more than 25 cells were
scored as individual colonies (CFU) on day 5 of culture.
Results are presented as average CFU-GM/2.5 × 105 spleen
cells ± SD or total CFU/spleen ± SD.
Analysis of Colony-Forming Cell Phenotype
Cells from CFU cultures were recovered after the
methycellulose medium was dissolved. Cultures were
treated with cellulase (1 U/mL) for 30 minutes at 37°C, fol-
lowed by 2 washes with PBS containing 0.5% BSA and
0.02% NaZ3. The cells were then stained with FITC-
conjugated anti-Ly5.1 and PE-conjugated anti-H-2Kb mAb
(Pharmingen). The phenotypes (Ly5.1+H-2Kb+, donor mar-
row origin; Ly5.1–H-2Kb+, donor T-cell/donor spleen ori-
gin; H-2Kb–, host origin) of the colony-forming cells were
determined by analysis with a FACScan system.
Peripheral Blood Chimerism Analysis
Blood samples of recipients were collected at various
time points after BMT. Red blood cells were removed by
2 rounds of ammonium chloride potassium treatment.
Mononuclear cells were stained as described above with anti-
H-2Kb and anti-Ly5.1 mAbs. Percentage of donor BM-
derived (Ly5.1+Kb+) cells was determined with ﬂow cytometry
(FACScan). Forward and side-angle light scatter was used to
establish analytical gates containing predominantly lymphoid
or nonlymphoid (monocyte/granulocytes) populations.
Lineage-Negative Donor Marrow Cell Migration to
Host BM
Murine BM mononuclear cells (from B6-Ly5.1 mice)
were depleted of cells expressing markers of lineage com-
mitment (CD3, CD4, CD8, Gr-1, Mac-1, Ter-119, and
B220). Lineage negative (lin–) cells were labeled with
0.1 µM carboxyfluorescein diacetete succinimidyl ester
(CFDA-SE) (Molecular Probes, Eugene, OR) according to
the manufacturer’s instructions. These cells then were incu-
bated either alone or with an equal number of Miltenyi
MACS purified CD8+ cells (either from wild-type or cdd-
deﬁcient T-cells) for 2 to 3 hours. Lin– cells alone (2 × 105
per mouse) or with 2 × 105 CD8+ T-cells were then injected
into the tail vein of 6- to 8-week-old C57BL/6 mice that
had been lethally irradiated (10 Gy) 24 hours previously.
Mice were then euthanized after 6 hours, and the levels of
transplanted cells in the BM were measured through the
detection of CFDA-SE+ cells by ﬂow cytometry.
Statistical Analysis
Data were analyzed with a Student 2-tailed unpaired
t test and one-way ANOVA. The confidence interval was
95%. A P value <.05 was considered signiﬁcant.
RESULTS
Early Presence of Lineage-Committed Donor
Progenitor Cells in Recipient Spleens Is Supported 
by Wild-Type Donor T-Cells as well as Donor T-Cells
That Lack FasL and Perforin Function
After irradiation and BMT, donor progenitor cells rapidly
enter the recipient spleen, a temporary site of extramedullary
hematopoiesis in the mouse. The initial seeding and expan-
sion of donor marrow cells can therefore be examined by
evaluation of the presence and number of colony-forming
cells of donor origin in the host spleen early (day 5) post-
BMT. To define facilitating activity in the transplantation
model, we found it necessary to identify a dose of host TBI
such that engraftment of donor progenitor cells required
addition of a facilitating cell population. BALB/c recipients
initially received transplants of TCD B6-Ly5.1 BM cells
24 hours after receiving varying doses of TBI. The hosts were
then assessed by examination of CFU-GM activity in the
recipient spleen 5 days after transplantation for detection of
the presence of progenitor cells (Figure 1). The results indi-
cated that at a dose of 6.0 Gy, strong host resistance remained
intact, evidenced by virtually complete rejection of 5 × 106
donor B6-TCD marrow. However, after 7.5 Gy TBI, signiﬁ-
cant numbers of CFUs were routinely detected in these
recipients (Figure 1). On the basis of these observations, a
dose of 7.5 Gy was considered a level that would enable the
sensitive detection of donor facilitation activity.
To examine the role of T-cells in this early appearance
of donor progenitor cells, we added spleen + lymph node
cells containing increasing numbers of T-cells from wild-
type or cytotoxically double-deficient (B6-cdd) donors to
the wild-type congenic (B6-Ly5.1) BM inoculum. CFU-GM
assay revealed that 7.5 Gy–conditioned hosts receiving BM
exhibited only a very low number of CFU as predicted from
the previous results (Figure 2). However, the addition of
donor T-cells, with or without functional Fas ligand and
perforin, significantly increased (>1 log) the number of
colony-forming cells in the host spleens (Figure 2). Anti-
body staining conclusively demonstrated that virtually all
colonies detected were derived from donor BM (data not
shown). At T-cell doses of 1 × 106, both B6-wt and B6-cdd
cells supported the presence of donor progenitor cells in the
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BALB/c spleens 5 days post-BMT. The supporting effect
remained strong even when the irradiation dose was
decreased to 5.5 Gy (Figure 2). The differences between the
number of colonies from recipients of wild-type B6 and B6-
cdd T-cells were not significant after either 7.5 Gy or
5.5 Gy irradiation (Figure 2). Results of two additional inde-
pendent experiments with B6-cdd T-cells corroborated
these observations (data not shown). These results therefore
showed that donor T-cells lacking functional Fas ligand and
perforin-dependent pathways could support the initial seed-
ing of allogeneic progenitor cells in recipients post-BMT.
CD8+ Donor T-Cells Support the Persistence of
Donor Chimerism
Disparities between the ability of CD4+ and CD8+ T-cell
subpopulations to support allogeneic donor BM cell engraft-
ment have been reported [7,12]. Highly enriched B6-wt
CD8+ donor T-cells were generated with anti-CD8 mAb con-
jugated magnetic beads and selection on a MACS column.
Spleen colony-forming assays on days 5 and 12 post-BMT
showed that the addition of CD4+ T-cells with CD8+ cells did
not enhance the support of progenitor cell presence by CD8+
T-cells alone (Figures 3A and 3B). It was important that
equivalent numbers of donor B220+ cells failed to support the
presence of donor progenitor cells in the host spleen. Com-
pared with the results for recipients receiving BM alone, no
significant increase in colony-forming cells was observed
post-BMT when the enriched B6 H-2b B-cell population was
added to the syngeneic BM inoculum. These observations
demonstrate that T-cell function is required for this process.
Long-term engraftment was assessed by peripheral blood
chimerism in the recipients. Previous results indicated that
after 7.5 Gy TBI, TCD allogeneic BM established periph-
eral donor chimerism in approximately 20% of the recipients
assessed 12 weeks post-BMT (data not shown). For these
studies, recipients were exposed to 5.5 Gy TBI to ensure
uniform rejection of all Ly5.1+ H-2b+ donor BM grafts post-
BMT. Blood samples were collected weekly after BMT, and
PBMC were analyzed with anti-H-2Kb and anti-Ly5.1 mAbs
for determination of donor marrow–derived chimerism
(double-positive staining) for up to 3 months posttransplan-
tation. Our initial observations indicated that both B6-wt
and B6-cdd spleen + lymph node inocula containing T-cells
were able to support detectable chimerism for the ﬁrst sev-
eral weeks post-BMT (Figure 2 and data not shown). How-
ever, only recipients of cytotoxically normal B6-wt T-cells
maintained long-term, stable donor chimerism. In accor-
dance with the observations early post-BMT (Figures 3A and
3B), ﬁndings at examinations of peripheral blood chimerism
over a 3-month period demonstrated that only BM grafts
containing donor CD8+ T-cells resulted in long-term stable,
multilineage donor chimerism (Figures 3C and 3D). Allo-
geneic marrow grafts without added T-cells or with B220+
(B-cell)-enriched populations did not show persistent
chimerism or establishment of engraftment (Figure 3).
Donor lymphoid chimerism was extremely transient in
recipients of marrow alone or with B220+ or CD4+ or B220+
cells (Figure 3C), whereas granulocytic chimerism persisted
for several weeks after transplantation in these groups (Fig-
ure 3D). In summary, BM transplanted with CD8+ and CD4+
T-cells or with only CD8+ T-cells efficiently and equally
engrafted (Figures 3C and 3D), whereas the addition of only
CD4+ T-cells to the BM failed to establish long-term
engraftment (Figures 3C and 3D). These findings agreed
with previous ﬁndings by others [13].
Figure 1. Strong host resistance after 6.0 Gy TBI. BALB/c recipients
(n = 3 per group) were irradiated with varying doses of TBI as indi-
cated. Twenty-four hours later, 5 × 105 or 5 × 106 TCD B6-Ly5.1 BM
cells were transplanted. Five days after transplantation, the colony-
forming activity of recipient spleen cells measured with CFU-GM
assay was assessed for determination of the effect of TBI dosage on
host resistance. P values: 9.0 Gy versus 8.5 Gy, P = .0010; 8.5 Gy versus
7.5 Gy, P = .036; 7.5 Gy versus 6.0 Gy, P = .0007.
Figure 2. Donor T-cells lacking Fas ligand and perforin can support
donor progenitor presence early post-BMT after nonmyeloablative
host conditioning. Twenty-four hours after 7.5 Gy (left) or 5.5 Gy
(right) TBI, 5 × 106 TCD B6-Ly5.1 BM cells were transplanted into
BALB/c recipients (3 per group) together with 1 × 106 T-cells from
B6-wt or B6-cdd donors. The spleen cells were analyzed for CFU-GM
on day 5. Spleen cells obtained from mice receiving BM cells alone
failed to generate signiﬁcant CFU activity. Total CFU-GM spleen at
7.5 Gy: B6-cdd T-cells, 3535 ± 851; B6-wt T-cells, 3684 ± 928, P =
.059. Total CFU-GM spleen at 5.5 Gy: B6-cdd T-cells, 2165 ± 148;
B6-wt T-cells, 2701 ± 155, P = .268.
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CD8+ T-Cell Cytotoxic Function Is Required for 
Long-Term Engraftment but Not to Support Initial
Allogeneic Progenitor Cell Presence in the
Recipient’s Spleen
We evaluated the importance of the 2 principal cytotoxic
T-cell pathways, that is, Fas ligand and perforin-dependent
killing, to determine the contribution of these pathways to
the promotion of donor BM engraftment. We obtained 1 ×
106 highly enriched CD8+ T-cells from wild-type (B6-wt),
gld (B6-gld), perforin knock-out (B6-pko) or cytotoxically
double-deﬁcient (B6-cdd) donors by positive selection with
MACS cell separation columns. The enriched T-cells were
transplanted with 5 × 106 TCD B6-Ly5.1 BM cells into 5.5
Gy irradiated BALB/c recipients (Figure 4A). All 4 CD8+
T-cell populations supported donor CFU-GM progenitor
cell presence in day 5 recipient spleen regardless of the cyto-
toxic deﬁciency (Figure 4A). However, unlike B6-wt and B6-
gld donor CD8+ T-cells, both B6-pko and B6-cdd CD8+
T-cells failed to support stable long-term donor lymphoid
and nonlymphoid chimerism in the recipients (Figures 4B
and 4C). In agreement with these observations, the number
of colony-forming cells in the spleen and BM of recipients
receiving B6-pko donor CD8+ T-cells decreased in compari-
son with the number of B6-wt and B6-gld donor CD8+
T-cells observed as early as day 14 posttransplantation (data
not shown). By 4 weeks after transplantation, a significant
percentage of annexin V+ cells (data not shown) was detected
in recipients of B6-cdd T-cells. A very small fraction was
detected in recipients of B6-wt T-cells. Identiﬁcation of the
large number of apoptotic donor cells in the former was con-
sistent with the ensuing loss of chimerism after BM trans-
plantation with CD8+ B6-cdd donor T-cells. In total, these
results uphold the notion that cytotoxic function by T-cells
aiding engraftment is not required to support the initial
presence of donor progenitor cells in the recipient; however,
perforin-dependent donor T-cell function is required to
maintain long-term allogeneic engraftment post-BMT.
CD8+ T-cells from Normal and Cytotoxically Deficient
Mice Increase the Homing of Lin– Progenitor Cells to
Recipient Marrow Early Posttransplantation
To determine whether donor T-cells could provide some
supportive function in the absence of a host barrier, we pre-
pared CD8 T-cells and transplanted them with enriched lin–
donor BM cells into lethally irradiated syngeneic B6 recipient
mice (Table). The number of CFDA-SE–labeled progenitor
cells in the BM of recipient mice 6 hours after infusion
increased approximately 50% when B6-wt CD8 T-cells
were present in the inoculum (Table). CD8+ T-cells from B6-
cdd mice increased the numbers of transplanted lin– cells in
recipient BM to virtually identical levels. In separate experi-
ments, CD8 T-cells from peripheral blood yielded essentially
Figure 3. Donor CD8+ T-cells are capable of supporting the initial presence of donor progenitor cells and maintaining long-term engraftment after
allogeneic MHC class I/II mismatched BMT. B6-wt CD4+ and CD8+ T-cells and B220+ B-cell–enriched populations were obtained by positive enrich-
ment with Miltenyi MACS magnetic columns. BALB/c recipients were irradiated with 5.5 Gy TBI 4 hours before transplantation with 5 × 106 TCD
B6-Ly5.1 BM alone or with addition of 1 × 106 enriched CD8+ T-cells or 1 × 106 CD4+ plus CD8+ (2:1) T-cells or 1 × 106 B220+ cells. Spleen CFU-
GM assay was performed 5 days (A) and 12 days (B) later. Peripheral blood samples were collected at different time points and stained for donor
chimerism with anti-H-2Kb and anti-Ly5.1 mAbs. Donor chimerism was determined by analysis with FACScan (C). Representative histograms of both
lymphoid and granuloid cells (D) demonstrate multilineage peripheral chimerism obtained from recipients of highly puriﬁed B6-wt CD8+ T-cells.
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the same results (data not shown). These ﬁndings illustrate
that donor T-cells can function to support increased homing
of progenitor cells to the host marrow early posttransplanta-
tion and demonstrate that such function does not require
perforin or FasL-mediated cytotoxicity by the CD8 T-cells.
To examine whether CD8 T-cells could enhance the
number of colony-forming units–culture in recipients fol-
lowing syngeneic BMT, we transplanted BM-TCD with B6-
wt or B6-cdd CD8 T-cells (Figure 5). B6 recipients were
conditioned with 5.5 Gy TBI, and 2 × 106 BM cells were
transplanted 1 day later alone or together with the puriﬁed
syngeneic CD8 T-cells. Five days after transplantation,
CFU–IL-3 cultures were established from pooled spleen
cells (n = 2 or 3 recipients per group). B6-GFP BM was used
to verify the donor origin of the colonies detected (data
not shown). Cultures established from all groups of recipi-
ents contained CFU–IL-3. No differences (P > .05) were
observed in the CFU–IL-3 numbers between recipients of
marrow alone or marrow and CD8 T-cells (Figure 5). An
independent experiment examining B6-wt CD8 T-cells was
performed to examine CFU–IL-3 support in the marrow
and spleen 7 days posttransplantation. The numbers of
CFU in the marrow and spleen compartments of recipients
of BM only or with syngeneic CD8 T-cells also were not
different. In summary, syngeneic CD8 T-cells did not aug-
ment the CFU–IL-3 activity of syngeneic BM transplanted
into syngeneic, sublethally irradiated recipients.
DISCUSSION
A requisite goal of allogeneic BMT is the accomplish-
ment of long-term multilineage hematopoietic engraftment
in the recipient. Marrow/progenitor cell allograft rejection
can result from immunological responses, such as host resis-
tance in the recipient after transplantation [14-21]. Despite
rigorous host immunosuppression before transplantation of
progenitor cell–containing inoculum, considerable resistance
remains intact. Experimental studies as well as clinical obser-
vations have shown that TCD marrow or progenitor-enriched
inoculum has increased susceptibility to host resistance as
evidenced by an increased incidence of graft failure with
TCD versus non-TCD inoculum [22-26]. These observa-
tions support the notion that T-cells can perform necessary
functions to support successful engraftment.Figure 4. Neither Fas ligand nor perforin function is required to sup-
port the early presence of functional donor CFU-GM, but perforin is
required for maintaining long-term engraftment of donor marrow.
BALB/c recipients were irradiated with 5.5 Gy TBI and given transplants
of 5 × 106 TCD B6-Ly5.1 BM cells plus 1 × 106 highly enriched CD8+
T-cells from B6-wt (group B), B6-gld (group C), B6-pko (group D), or
B6-cdd (group E) donors. Recipients of BM only (group A) were used as
negative controls. On day 5, spleen cells of the recipients were harvested
and analyzed for CFU-GM (A). (P values: group A versus B, C, D, or E,
P < .0001; group B versus C, P = 0.38; group B versus D, P = 0.14; group
B versus group E, P = 0.93). Peripheral blood samples were collected at
different time points and stained with anti H-2Kb and anti-Ly5.1 mAbs
for determination of donor chimerism. The donor chimerism of lym-
phoid (B) and granuloid (C) lineages was determined by analysis with a
FACScan system. Representative histograms of the peripheral chimerism
(C) of an individual recipient of B6-pko CD8+ T-cells.
Transplantation of Highly Enriched CD8 T-Cells and Lin– Donor BM Cells
into Lethally Irradiated Syngeneic B6 Recipient Mice
Lin– BM Lin– BM + cdd Lin– BM + wt
Experiment* Alone CD8+ T-Cells CD8+ T-Cells
1 90 133 (147%)† 140 (155%)†
2 73 133 (182%) 121 (166%)
3 84 119 (142%) 129 (153%)
*Individual mice (10 Gy) in each experiment were injected IV with
2 × 105 CFDA-SE–labeled B6 lineage–negative BM (lin– BM) cells
alone or with puriﬁed (2 × 105) CD8+ T-cells. Six hours later the ani-
mals were killed, and BM from 2 tibias and 2 femurs of each mouse was
collected and analyzed by ﬂow cytometry for injected cells.
†Values represent the number of CFDA-SE–labeled cells per 1 ×
105 BM cells. Numbers in parentheses represents the percentage
increase in cell numbers compared with the numbers of lin– BM cells
transplanted alone. Combining results from the three independent
experiments demonstrates that Lin–BM + cdd CD8’s (123+/–4.7) or
Lin–BM + wt CD8’s (130+/–5.5) versus Lin–BM alone (82.3+/–5.0),
P < .01, Lin–BM + cdd CD8’s versus Lin–BM + wt CD8’s, P > .05.
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A number of studies removing or adding defined cell
types to allogeneic stem cell inoculum have shown that non-
progenitor populations can promote or facilitate long-term
multilineage engraftment [27-32]. The capacity to facilitate
has been primarily assessed by evaluation of the level of
engraftment established in the allogeneic recipient 4 or more
weeks after progenitor cell transplantation. Although consid-
erable investigation has deﬁned a number of distinct support-
ing cell populations, the overall process by which facilitation
results in long-term engraftment remains unclear. To
approach this question, we are investigating the early as well
as later period posttransplantation to examine and compare
the functional requirements of, and activity effected by,
T-cells for promotion of the initial seeding of donor pro-
genitor populations as well as persistent long-term multilin-
eage engraftment. The findings in this study show that
T-cells lacking perforin and/or FasL function have the capac-
ity to promote the early presence of MHC class I/II mis-
matched donor progenitor cells in the recipient’s hemato-
poietic compartment after transplantation into sublethally
irradiated hosts. Competent B-cell–enriched lymphoid popu-
lations do not have such functions. In contrast to these obser-
vations, persisting multilineage donor engraftment was
clearly dependent on intact perforin function in the T-cells
examined.
The addition of marrow-derived and peripheral TcR+
cells, including both TcRα/β+ [27] and TcR γδ+ T-cells [29], as
well as NK [28] and TcR–CD8+ cells [32] to progenitor grafts
has been demonstrated to promote engraftment in experi-
mental BMT models. CD8+ peripheral T-cells were found by
Martin and colleagues to support engraftment of allogeneic
marrow as determined by peripheral donor cell chimerism
more than 4 weeks post-BMT [13]. Subsequent studies by this
group showed that cytotoxically deﬁcient CD8+ T-cells were
impaired in their capacity to support this engraftment [12].
Speciﬁcally, perforin, but not granzyme B– or FasL-deﬁcient
T-cells, failed to support multilineage engraftment 1 month
posttransplantation [12]. Findings in the present study cor-
roborated a requirement for perforin function in peripheral
T-cell–facilitating populations. In contrast, a recent study
showed that the absence of granule-dependent cytotoxicity
did not detectably impair the ability of CD8+ BM T-cells to
support prolonged engraftment after transplantation of puri-
ﬁed MHC-mismatched stem cell populations [32].
It has been reported that after BMT, 2 phases of donor cell
engraftment can be observed: an early period of reconstitution
(radioprotective) occurring immediately after transplantation fol-
lowed by a slower but more stable long-term chimerism [7,33].
Experiments underway in this laboratory have shown that in
contrast to the splenic compartment in normal adult mice, which
possesses <0.1% of the total CFU–IL-3 potential contained in
the combined marrow + spleen compartments, the splenic com-
partment of mice subjected to syngeneic BMT contains approxi-
mately 5% to 30% of this potential during the ﬁrst 1 to 2 weeks
after transplantation. These levels diminish to almost homeostatic
levels during the next 2 weeks (A. Shatry and R.B.L., unpub-
lished observations). Splenectomy of mice prior to BMT clearly
impacted, that is, augmented, the CFU–IL-3 marrow numbers
early after BMT (A. Shatry and R.B.L., unpublished observa-
tions). These ﬁndings may indicate that interactions between
these compartments early post-BMT are critical for determining
committed donor progenitor cell numbers in recipients and sup-
port the notion that the spleen is a functionally important host
hematopoietic compartment during the first month after
hematopoietic progenitor cell transplantation.
The presence of donor-derived progenitor cells early
posttransplantation could be assessed by examination of the
presence of CFU-GM in the host spleen. After TCD BMT
with wild-type B6 (H-2b) donor T-cells to facilitate donor
BM cell engraftment, the presence or absence of signiﬁcant
numbers of CFU-GM numbers in the host BALB/c (H-2d)
spleen on day 5 post-BMT correlated with successful or failed
long-term engraftment of donor marrow. However, when
cytotoxically deﬁcient donor T-cells were included with the
TCD-BM donor graft, a clear discrepancy was observed
between early and late donor cell presence dependent on the
individual lytic pathway absent in the facilitating population.
The presence of lineage-committed donor progenitor cells in
the host spleen 5 days posttransplantation after addition of
cytotoxically defective CD8+ T-cells did not necessarily result
in long-term donor chimerism. These ﬁndings suggested that
different functions of donor T-cells could be required to sup-
port the early seeding of donor progenitor cells versus those
necessary for support of long-term engraftment. Recent stud-
ies have shown that addition of peripheral CD8+ T-cells to
CD34+ stem cell populations increases the level of stem cell
migration to hematopoietic compartments after infusion [34].
Interestingly, in syngeneic lethally irradiated BMT recipients
in this study, cytotoxically deﬁcient, as well as normal T-cells,
had the capacity to promote the migration of increased
numbers of progenitor cells to the marrow compartment soon
Figure 5. Donor CD8+ T-cells do not support increased progenitor
activity after syngeneic BMT following sublethal irradiation of recipi-
ents. B6 recipients (n = 2 or 3 per group) were irradiated with 5.5 Gy
TBI and given transplants the following day of 2 × 106 TCD B6-GFP
BM cells alone or BM plus 2 × 106 highly enriched CD8+ T-cells from
B6-wt or B6-cdd donors. On day 5, spleen cells of the recipients were
harvested, pooled, and analyzed for CFU–IL-3. Donor origin of
colonies was confirmed by GFP fluorescence. Allogeneic BALB/c
recipients were also irradiated and given transplants in an identical
fashion with either the same B6-GFP BM alone or with B6-wt CD8+
T-cells. Total splenic CFU was obtained by multiplying the CFU fre-
quency by the total number of spleen cells. B6 recipients of BM only
(321 ± 34.7) versus BM + B6-wt CD8 (285 ± 49.2) or BM + B6-cdd
CD8 (282 ± 57), P > .05. BALB/c recipients of BM only (36 ± 17.6)
versus BM + B6-wt CD8 (159 ± 20.4), P < .01.
Facilitating Cell Cytotoxic Function in Engraftment
595B B & M T
after infusion. These observations were made (1) under condi-
tions in which cytotoxic function by the donor T-cells was not
required to overcome resistance and (2) with B6-cdd CD8 T-cells.
Therefore these data would appear to exclude any role for per-
forin/FasL cytotoxic function in such T-cell activity. To deter-
mine whether syngeneic T-cells had the capacity to support
enhanced CFU early after syngeneic BMT in our model, we
gave sublethally irradiated B6 mice transplants of B6 BM-
TCD alone or BM together with B6-wt or B6-cdd CD8
T-cells. The inability of these cotransplanted populations to
increase CFU–IL-3 levels after syngeneic BMT supports the
notion that activation of these CD8 T-cells occurring in the
B6→BALB/c allogeneic BMT experiments is required for
their affect on subsequent (1-2 weeks) progenitor cell activity.
It may be interesting to examine CFU–IL-3 after syngeneic
BMT under conditions that strongly activate putative syn-
geneic CD8 supportive populations.
Regarding long-term reconstitution, the present results
conﬁrmed that CD8+ peripheral T-cells can be effective in
maintaining donor-derived multilineage chimerism in the
allogeneic host [12,13]. Consistent with previous findings,
T-cell perforin function was crucial for this activity [12].
When recipients in the present study were given transplants
of TCD BM with the addition of donor T-cells lacking per-
forin function, although these T-cells promoted the early
presence of donor CFU-GM in the recipient’s spleen, donor
chimerism began to decrease 4 to 6 weeks posttransplanta-
tion. These ﬁndings indicated that T-cells must have cyto-
toxic function if they are to successfully support long-term
engraftment. However, such cytotoxic function is apparently
unnecessary in support of the initial/early presence and
function of progenitor cells in the hematopoietic compart-
ment (Figure 6). Such observations further suggest that the
mechanism of facilitation is complex and is likely to involve
a multistep/multifunctional process.
The present studies also demonstrated that donor T-cells
simultaneously lacking FasL and perforin function were
capable of supporting the early presence of donor-derived
progenitor cells in the recipient spleen. Thus the 2 major
donor cytotoxic T-cell pathways are not required by CD8+
T-cells to promote donor progenitor cell presence early
post-BMT. Alternatively, other T-cell cytotoxic functions or
cell populations could be important in supporting the pres-
ence of donor progenitor cells. Besides FasL and perforin,
cytotoxic pathways such as tumor necrosis factor α (TNF-α)
[35], TNF-related apoptosis-inducing ligand (TRAIL) [36],
and transforming growth factor β (TGF-β) [37] have been
suggested to play some role in hematopoiesis. However, the
involvement of these molecules in supporting donor BM cell
engraftment remains undefined. The failure of enriched
B-cells to promote splenic donor CFU activity indicated that
a speciﬁc T-cell, but not B-cell, function is required for these
observations and that the function is not passive, such as
“diverting” host resistance by “ﬂooding” donor antigen into
recipients. This result is consistent with the finding that
although direct antihost responses by facilitating populations
cannot be excluded in a number of studies, donor T-cells
have been found to support engraftment without direct
recognition of host antigen [38,39]. It also has been reported
that IL-1α was able to augment donor marrow engraftment
and hematopoietic reconstitution [40]. Other investigators
have reported that HSC treated with IL-11 and stem cell
factor or anti–TGF-β exhibited a dramatic increase in short-
term reconstitution after BMT [37,41,42]. The mechanism
whereby T-cells promote the initial presence and activity of
progenitor cells in the hematopoietic compartments of allo-
geneic recipients remains unclear and requires further study
for elucidation of the pathways involved.
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